Share this

Article Facebook

Twitter

Email You are free to share this article under the Attribution 4.0 International license. University Brown University

The brains of infants who carry a gene associated with an increased risk for Alzheimer’s disease develop differently than babies who don’t have the gene.

While this discovery is neither diagnostic nor predictive of Alzheimer’s, it could be a step toward understanding how the gene variant APOE ε4, confers risk much later in life.

[related]

Researchers imaged the brains of 162 healthy babies between the ages of two months and 25 months. All of the infants had DNA tests to see which variant of the APOE gene they carried. Sixty of them had the ε4 variant that has been linked to an increased risk of Alzheimer’s.

Using a special MRI technique designed to study sleeping infants, they compared the brains of ε4 carriers with non-carriers. They found that children who carry the APOE ε4 gene tended to have increased brain growth in areas in the frontal lobe, and decreased growth in areas in several areas in the middle and rear of the brain. The decreased growth was found in areas that tend to be affected in elderly patients who have Alzheimer’s disease.

Researchers emphasized the findings, published in JAMA Neurology, do not mean that any of the children in the study are destined to develop Alzheimer’s or that the brain changes detected are the first clinical signs of the disease.

What the findings do suggest, however, is that brains of APOE ε4 carriers tend to develop differently from those of non-ε4 carriers beginning very early in life. It is possible that these early changes provide a “foothold” for the later pathologies that lead to Alzheimer’s symptoms. Information from this study may be an important step toward understanding how this gene confers risk for Alzheimer’s, something that is not currently well understood.

“This work is about understanding how this gene influences brain development,” says Sean Deoni, assistant professor of engineering who oversees the Advanced Baby Imaging Lab at Brown University. “These results do not establish a direct link to the changes seen in Alzheimer’s patients, but with more research they may tell us something about how the gene contributes to Alzheimer’s risk later in life.”

Roles in blood and brain

The APOE ε4 variant linked to Alzheimer’s is present in about 25 percent of the US population. Not everyone who carries the gene gets Alzheimer’s, but 60 percent of people who develop the disease have at least one copy of the ε4 gene.

The gene is thought to have several different roles in the blood and brain, some of which remain to be clarified. For instance, it has been shown to participate in regulation of cholesterol, a molecule that is involved in the development of gray matter and white matter brain cells.

It has also been shown to participate in the regulation of amyloid, a brain protein that accumulates in Alzheimer’s and is now being targeted by investigational treatments. Studies are needed to clarify the ways in which APOE, human development, aging and other risk factors may conspire to produce the brain changes involved in Alzheimer’s disease.

The researchers used an MRI technique that quiets the MRI machine to a whisper, enabling the brains of healthy babies to be imaged while they sleep without medication. The technique also enables imaging of both gray matter—the part of the brain that contains neurons and nerve fibers—and white matter, which contains the fatty material that insulates the nerve fibers. Both gray and white matter are thought to have a role in Alzheimer’s. White matter growth begins shortly after birth and is an important measure of brain development.

Babies develop normally

“We’re in a good spot to be able to investigate how this gene influences development in healthy infants. These infants are not medicated and not showing any cognitive decline—quite the opposite, actually; they’re developing normally.”

There is no reason to believe that the children won’t continue to develop normally, Deoni says. There is no consistent evidence to suggest that ε4 carriers suffer any cognitive problems or developmental delay. And the areas of increased growth raise the possibility that the gene might actually confer some advantages to infants early on.

Ultimately the researchers hope the findings could lead to new strategies for preventing a disease that currently affects more than 5.2 million people in the US alone.

“It may sound scary that we could detect these brain differences in infants,” says Eric Reiman, executive director of the Banner Alzheimer’s Institute in Arizona and another senior author on the paper.

“But it is our sincere hope that an understanding of the earliest brain changes involved in the predisposition to Alzheimer’s will help researchers find treatments to prevent the clinical onset of Alzheimer’s disease—and do so long before these children become senior citizens.”

Researchers from the Translational Genomics Research Institute and the University of Southern California also participated in this study, which was supported by the National Institute of Mental Health and the National Institute on Aging, both part of the National Institutes of Health, and the state of Arizona.

Source: Brown University